Novel Antischizophrenia Treatments

Handbook of Experimental Pharmacology

Book 213
Springer Science & Business Media
2
Free sample

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Read more
5.0
2 total
Loading...

Additional Information

Publisher
Springer Science & Business Media
Read more
Published on
Oct 1, 2012
Read more
Pages
458
Read more
ISBN
9783642257582
Read more
Language
English
Read more
Genres
Medical / Pharmacology
Medical / Pharmacy
Medical / Psychiatry / Psychopharmacology
Psychology / Experimental Psychology
Psychology / Physiological Psychology
Read more
Content Protection
This content is DRM protected.
Read more

Reading information

Smartphones and Tablets

Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.

Laptops and Computers

You can read books purchased on Google Play using your computer's web browser.

eReaders and other devices

To read on e-ink devices like the Sony eReader or Barnes & Noble Nook, you'll need to download a file and transfer it to your device. Please follow the detailed Help center instructions to transfer the files to supported eReaders.
Ray Tokes is continuing the battle against big pharma as well as the tobacco industry in his latest book The Truth About CBD - Using Cannabidiol As A Medication - Real Life Stories and Case Studies Revealed.

Ray Tokes is standing on the front line of the CBD revolution, actively combating big pharma and tobacco's combined lobbying efforts and fictional claims against CBD through real life usage examples of Cannabidiol and actual documented case studies.

The Truth About CBD - Using Cannabidiol As A Medication - Real Life Stories and Case Studies Revealed is a collection of real life stories from all around the world, documenting the miraculous success when using Cannabidiol as a medication.

Revealing the risks that have been taken in hopes of regaining health and happiness when all other conventional medications have left a feeling of hopelessness.

Real life stories and documented case studies are finally revealed to put to rest all of the false claims surrounding CBD. Get the book filled with information that big pharma and the tobacco industry is actively trying to suppress.

Self treatment and medical research have pushed CBD to the forefront of a medical breakthrough.

Skeptics and medical professionals alike are left with no option but to believe - there is hope.

Discover the truth about CBD and get answers to important questions such as:

What Is CBD Oil and Where Does It Come From? - Ray Tokes gives a clear and concise answer as to what CBD is and is not as well as where it is derived from.

Why Is Cannabidiol a Useful Compound? - Ray Tokes explains what makes Cannabidiol a true medical break through.

What Makes Cannabidiol So Powerful? - Ray Tokes provides proof as to why Cannabidiol is a powerful medication.

What Illnesses Is Cannabidiol Currently Being Used to Treat? - Learn about the variety of uses for CBD.

What Are Some of the Different Ways to Use Cannabidiol? How Much Cannabidiol Is It Safe to Use? - Discover the unique ways to safely consume Cannabidiol and how much is safe to ingest at a time.

Has Medicinal Cannabidiol Ever Actually Worked for Anybody? - Ray Tokes provides real life usage examples of Cannabidiol.

What Are Medical Experts Saying About the Use of Cannabidiol? - Ray Tokes reveals documented case studies.

What Does the Future Hold for Cannabidiol Research and Investigation? - Learn what is around the corner for Cannabidiol.

Which Cannabidiol Products Are Approved and Trusted By the Market? - Discover which Cannabidiol products are safest and tips for buying different types of Cannabidiol products.

Find out what Ray Tokes thinks regarding the Regulation, Distribution, and Use of Cannabidiol.

Ray Tokes shares his vetted CBD vendor list. Get The Truth About CBD - Using Cannabidiol As A Medication - Real Life Stories and Case Studies Revealed today before it is removed from the bookshelves.
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics.

When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders.

Gerhard Gross, Ludwigshafen, Germany

Mark A. Geyer, La Jolla, CA

This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.

©2018 GoogleSite Terms of ServicePrivacyDevelopersArtistsAbout Google|Location: United StatesLanguage: English (United States)
By purchasing this item, you are transacting with Google Payments and agreeing to the Google Payments Terms of Service and Privacy Notice.